CD274 and non-small cell lung carcinoma: With the Keynote-042 study of chemotherapy versus pembrolizumab for PD-L1(+) NSCLC as an example,6 pembrolizumab was both 62% less toxic and 71% or 64% more efficacious when measuring improvement by median PFS or median OS, respectively.